BL0020

DRUG3 trials

Sponsors

Shanghai Best-Link Bioscience, LLC

Conditions

Advanced Solid TumorSmall Cell Carcinoma of Lung

Phase 1

Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors

Shanghai Best-Link Bioscience, LLCAdvanced Solid Tumor

Start: 2023-10-24End: 2025-02-28Target: 66Updated: 2023-11-29

A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy

Not yet recruitingNCT07414927

Shanghai Best-Link Bioscience, LLCSmall Cell Carcinoma of Lung

Start: 2026-03-27End: 2028-02-20Target: 48Updated: 2026-02-17

A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Not yet recruitingNCT07550842

Shanghai Best-Link Bioscience, LLCSmall Cell Carcinoma of Lung

Start: 2026-06-16End: 2028-08-18Target: 33Updated: 2026-04-24

Related Papers

BL0020, a novel tumor microenvironment (TME)-targeting nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Updated results from the small cell lung cancer (SCLC) subset of a phase 1 study.

Journal of Clinical Oncology2026-05-28